Several previous studies also demonstrated that CD82 represses TGF-β1-mediated EMT through regulation of different signaling pathways in various carcinoma types (Zhu et al., 2017; Zeng et al., 2018; Lee et al., 2019). This evidence concerns the gene TGFB1 and carcinoma.